Specifically, treatment of CRC with C. butyricum led to MYC degradation through enhanced proteasome‐mediated ubiquitination, and thus effectively mitigated MYC‐driven 5‐FU resistance and boosted anti‐PD‐1 immunotherapy effect [65]. This evidence concerns the gene MYC and colorectal carcinoma.